Molecular structure of Oseltamivir phosphate, CAS Number: 204255-11-8
Oseltamivir phosphate (CAS 204255-11-8)
See product citations (5)
Alternate Names:
(3R,4R,5S)-4-(Acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic Acid Ethyl Ester Phosphate; Oseltamir Phosphate
Application:
Oseltamivir phosphate is an antiviral agent
CAS Number:
204255-11-8
Purity:
≥99%
Molecular Weight:
410.40
Molecular Formula:
C16H28N2O4•H3PO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Oseltamivir Phosphate, an antiviral chemical, has many applications in the realm of virology research. Scientists explore its mechanism of action, which involves the inhibition of neuraminidase, an enzyme critical for the release and spread of viral particles in the influenza virus. This has a profound impact on understanding viral replication cycles and the development of resistance. Researchers are also examining how this compound affects the behavior and evolution of influenza viruses over time. Another research avenue includes its role as a standard in analytical chemistry, where it is used to develop and refine detection methods for antiviral substances in biological samples. Moreover, oseltamivir phosphate′s interaction with various biomolecules is studied to shed light on potential secondary effects and mechanisms within cellular systems.
Oseltamivir phosphate (CAS 204255-11-8) References
- Different synthetic strategies of oseltamivir phosphate: a potent influenza neuraminidase inhibitor. | Gong, J. and Xu, W. 2008. Curr Med Chem. 15: 3145-59. PMID: 19075659
- Synthesis of (-)-oseltamivir phosphate (Tamiflu) starting from cis-2,3-bis(hydroxymethyl)aziridine. | Oh, HS. and Kang, HY. 2012. J Org Chem. 77: 8792-6. PMID: 22970883
- Influenza and oseltamivir phosphate (Tamiflu) in infants: what you need to know. | Mortada, M., et al. 2014. Pediatr Nurs. 40: 16-20. PMID: 24757915
- Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness. | de Oliveira, JT., et al. 2015. PLoS One. 10: e0121590. PMID: 25850034
- Reductive amination assistance for quantification of oseltamivir phosphate and oseltamivir carboxylate by HPLC-MS/MS. | Huang, MF., et al. 2018. J Chromatogr B Analyt Technol Biomed Life Sci. 1087-1088: 23-28. PMID: 29702353
- Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate. | Carrez, R., et al. 2019. Antimicrob Agents Chemother. 63: PMID: 30962337
- Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys. | Loukotková, L., et al. 2020. Regul Toxicol Pharmacol. 112: 104569. PMID: 31927005
- Evaluating the effects of oseltamivir phosphate on platelet counts: a retrospective review. | Shaim, H., et al. 2020. Platelets. 31: 1080-1084. PMID: 31931672
- Development of Sustained Release Oseltamivir Phosphate Dry Powder Inhaler: In-Vitro Characterization and In-Vivo Toxicological Studies. | Sahastrabudhe, H., et al. 2020. Curr Drug Deliv. 17: 703-710. PMID: 32472998
- Adverse Effects of Oseltamivir Phosphate Therapy on the Liver of LDLR-/- Mice Without Any Benefit on Atherosclerosis and Thrombosis. | Bocquet, O., et al. 2021. J Cardiovasc Pharmacol. 77: 660-672. PMID: 33760798
- Oseltamivir phosphate loaded pegylated-Eudragit nanoparticles for lung cancer therapy: Characterization, prolonged release, cytotoxicity profile, apoptosis pathways and in vivo anti-angiogenic effect by using CAM assay. | Yurtdaş-Kırımlıoğlu, G., et al. 2022. Microvasc Res. 139: 104251. PMID: 34520775
- Effect of oseltamivir phosphate versus placebo on platelet recovery and plasma leakage in adults with dengue and thrombocytopenia; a phase 2, multicenter, double-blind, randomized trial. | Tunjungputri, RN., et al. 2022. PLoS Negl Trop Dis. 16: e0010051. PMID: 34995275
- Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases. | Qorri, B., et al. 2022. Cancers (Basel). 14: PMID: 35892853
- Characterization of two excipient interaction degradation products in oseltamivir phosphate powder for oral suspension by MS and NMR. | Yao, B., et al. 2022. J Mass Spectrom. 57: e4899. PMID: 36517208
Inhibitor of:
Carboxylesterase (CES), CMAS, CMV gH, Influenza A pb1, Influenza B NA, Neuramidase, from A. ureafaciens, Neuramidase, from V. cholerae, Neuraminidase, Neuraminidase, from C. perfringens, rotavirus C vp6, Rotavirus capsid, SIAE, Sialyltransferase 7D, Siglec-15, and Siglec-7.Activator of:
Influenza A Virus Hemagglutinin, Neu1, Neu2, Neuramidase, from V. cholerae, and Neuraminidase, from C. perfringens.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Oseltamivir phosphate, 10 mg | sc-208135 | 10 mg | $175.00 | |||
Oseltamivir phosphate, 200 mg | sc-208135A | 200 mg | $637.00 |